切换至 "中华医学电子期刊资源库"
高级检索
中华肺部疾病杂志(电子版)

中华肺部疾病杂志(电子版) ›› 2026, Vol. 19 ›› Issue (05) : 840 -848. doi: 10.3877/cma.j.issn.1674-6902.2026.05.018

论著

近10年肺癌脑转移研究现状及热点分析
杨小钰1,2, 田建辉1,2,†(), 罗斌1,2, 杨蕴1,2, 陆鑫熠1,2, 任胜祥3   
  1. 1200071　上海，上海中医药大学附属市中医医院肿瘤临床医学中心
    2200071　上海，上海中医药大学附属市中医医院肿瘤研究所
    3200433　上海，同济大学附属上海市肺科医院肿瘤内科
  • 收稿日期:2025-01-01 出版日期:2026-10-25
  • 通信作者: 田建辉
  • 基金资助:
    上海申康医院发展中心诊疗技术推广及优化管理项目课题(SHIDC22025212); 国家自然科学基金青年项目(82104943); 上海市卫生健康委员会领军人才项目(2022LJ014)

Current status and hotspot analysis of research on brain metastases from lung cancer in the past decade

Xiaoyu Yang1,2, Jianhui Tian1,2,†(), Bin Luo1,2, Yun Yang1,2, Xinyi Lu1,2, Shengxiang Ren3   

  1. 1Clinical Oncology Center, Shanghai Municipal Hospital of TCM, Shanghai University of TCM, Shanghai 200071, China
    2Institute of Traditional Chinese Medicine Oncology, Shanghai Municipal Hospital of Traditional Chinese Medicine Shanghai University of TCM, Shanghai 200071, China
    3Department of Lung Cancer, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai 200433, China
  • Received:2025-01-01 Published:2026-10-25
  • Corresponding author: Jianhui Tian
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

杨小钰, 田建辉, 罗斌, 杨蕴, 陆鑫熠, 任胜祥. 近10年肺癌脑转移研究现状及热点分析[J/OL]. 中华肺部疾病杂志(电子版), 2026, 19(05): 840-848.

Xiaoyu Yang, Jianhui Tian, Bin Luo, Yun Yang, Xinyi Lu, Shengxiang Ren. Current status and hotspot analysis of research on brain metastases from lung cancer in the past decade[J/OL]. Chinese Journal of Lung Diseases(Electronic Edition), 2026, 19(05): 840-848.

目的

通过对肺癌脑转移(brain metastases of lung cancer)相关研究进行文献计量学统计及可视化分析，探讨近10年该领域的研究热点和发展趋势。

方法

基于中国知网、Web of Science核心数据库，利用Citespace、VOSviewer及R软件对2014年至2024年发表文章进行文献计量学统计及可视化分析，通过对发表文章的年度分布、被引情况、国家/地区、机构和关键词等进行可视化分析，并对关键词进行共现分析、聚类分析及突现分析。

结果

中文文献共检索出1 349篇，英文文献共检索出3 352篇，其中肺癌脑转移免疫治疗相关文献为376篇，对WOS数据库整体分析，英文发文量年增长速度为15.15%，涉及17 814名作者，53 537篇参考文献。通过对1 349篇中国知网及3 352篇WOS核心数据库中肺癌脑转移领域文献进行可视化分析显示，该领域发文量呈逐年上涨趋势，中国和美国位居英文发文量前两位，分别发文1 224篇、887篇，约占近10年各国总发量的60%，中文、英文发文量最多的机构分别为郑州大学、Hanvard University，中文、英文文献产出最多的作者分别为吴一龙、Ahn，Myung-Ju，关键词分析提示靶向治疗、化疗、放疗、免疫治疗及联合治疗的临床研究是热点。

结论

近10年肺癌脑转移领域持续发展，治疗方案的更迭延长患者生存时间，免疫及联合治疗打破既往疗效壁垒，未来多学科融合将实现肺癌脑转移精准化治疗。

关键词: 支气管肺癌, 脑转移, 文献计量学, 免疫治疗
Objective

Through bibliometric statistical analysis and visual analysis of studies related to brain metastasis of lung cancer, this study aims to explore the research hotspots and development trends in this field over the past 10 years.

Methods

A total of 1, 349 Chinese-language articles and 3, 352 English-language articles were retrieved, of which 376 were related to immunotherapy for brain metastases from lung cancer. An overall analysis of the WOS database showed that the annual growth rate of English-language publications was 15.15%, involving 17, 814 authors and 53, 537 references. Based on the core database of CNKI and Web of Science, Citespace was used to explore the research hotspot and development trend of brain metastases related to lung cancer in recent 10 years through bibliometric statistics and visual analysis VOS viewer and R software conducted bibliometrics statistics and visual analysis of the published articles from 2014 to 2024, conducted visual analysis of the annual distribution and citation of the published articles, national and regional institutions and keywords, and conducted co-occurrence analysis of the keywords cluster analysis and emergence analysis.

Results

Through the visual analysis of 1 349 CNKI and 3 352 WOS core database literature in the field of lung cancer brain metastasis, the number of papers published in this field showed an increasing trend year by year, China and United States ranked the top two in English, published 1, 224 and 887 articles, respectively, accounting for approximately 60% of the total publications of all countries in the past decade. Zhengzhou University and Hanvard University were the institutions with the largest number of Chinese and English articles, and the authors with the most Chinese and English literature output were Wu Yilong, Ahn and Myung-Ju, respectively, and keyword analysis suggested targeted therapy and chemotherapy, radiotherapy, immunotherapy and combination therapy are hot spots.

Conclusion

In the past 10 years, the field of lung cancer brain metastases has continued to develop, the change of treatment protocols has extended the survival time, and immunization and combination therapy have become the mainstream to break the therapeutic barrier. In the future, multidisciplinary integration will realize the precision treatment of lung cancer brain metastases.

Key words: Bronchogenic carcinoma, Brain metastases, Bibliometrics, Immunotherapy
图1 图A为CNKI文献检索流程图；图B为WOS文献检索流程图
图2 CKNI及WOS发文量趋势
表1 前10位国家/地区发文量及中心性
序号 国家/地区 发文量 中心性
1 中国 1 224 0.02
2 美国 887 0.04
3 日本 309 0.01
4 德国 280 0.14
5 韩国 231 0.08
6 意大利 197 0.04
7 法国 194 0.15
8 加拿大 159 0.14
9 台湾 136 0.14
10 西班牙 128 0.13
表2 前10位机构发文量及中心性
序号 机构(中国知网) 发文量 中心性 机构(WOS) 发文量 中心性
1 郑州大学 39 0.00 Hanvard University 163 0.06
2 南昌大学 33 0.00 UNICANCER 128 0.17
3 河北医科大学 32 0.00 Shandong First Medical University & Shandong Academy of Medical Sciences 109 0.01
4 中国医科大学 32 0.00 University of Texas System 108 0.03
5 山东大学 27 0.00 Chinese academy of medical sciences-peking union medical college 99 0.00
6 大连医科大学 27 0.00 Massachusetts General Hospital 93 0.05
7 天津医科大学 24 0.00 Sungkyunkwan University (SKKU) 85 0.02
8 北京协和医学院 24 0.00 Fudan University 85 0.00
9 吉林大学 23 0.00 UTMD Anderson Cancer Center 84 0.05
10 苏州大学 22 0.00 University of California System 79 0.14
图3 图A为CNKI发文作者合作可视化网络；图B为WOS发文作者合作可视化网络
表3 发文量前10位作者及中心性
序号 作者(中国知网) 发文量 中心性 作者(WOS) 发文量 中心性
1 吴一龙 4 0.00 Ahn，Myung-Ju 29 0.07
2 苏　雷 3 0.00 Kim，Dong-Wan 25 0.12
3 秦丽娟 3 0.00 Shaw，Alice T 23 0.05
4 霍　燃 3 0.00 Zhou，Caicun 22 0.11
5 李洪伟 3 0.00 Wu，Yi-Long 20 0.1
6 王家雄 3 0.00 Yu，Jinming 19 0.31
7 刘艳萍 3 0.00 Camidge，DRoss 19 0.23
8 李　想 3 0.00 Felip，Enriqueta 16 0.01
9 前梅娥 3 0.00 Park，Keunchil 15 0.06
10 李小芳 3 0.00 Brastianos，Priscilla K 15 0.04
表4 WOS共被引频次≥100次文献
序号 文　献 DOI 频次 中心性
1 Soria JC，2018，NEWENGLJME 10.1056/NEJMoa1713137 204 0.10
2 Sperduto PW，2017，JAMA ONCOL 10.1001/jamaoncol.2016.3834 148 0.14
3 Ramalingam S8，2020，NEWENGLJMED 10.1056/NEJMoa1913662 140 0.07
4 Goldberg SB，2016，LANCET ONCOL 10.1016/S1470-2045(16)30053-5 127 0.09
5 Brown PD，2016，JAMA-JAM MED ASS0C 10.1001/jama.2016.9839 121 0.05
6 Reungwetwattana T，2018, JCLIN ONCOL 10.1200/JCO.2018.78.3118 121 0.07
7 SungH，2021，CA-CANCERJCLIN 10.3322/caac.21660 118 0.00
8 Peters S，2017，NEWENGLJMED 10.1056/NEJMoa1704795 118 0.10
9 Goldberg SB，2020，LANCET ONCOL 10.1016/S1470-2045(20)30111-X 112 0.08
图4 图A为CNKI关键词密度；图B为WOS关键词密度；图C为CNKI关键词共现可视化网络；图D为WOS关键词共现可视化网络
表5 中英文文献前10位关键词
序号 Keywords(中国知网) 频次 中心性 Keywords(WOS) 频次 中心性
1 脑转移 484 0.36 brain metastases 1 172 0.21
2 肺癌 197 0.44 survival 734 0.02
3 预后 126 0.15 brain metastasis 640 0.11
4 脑转移瘤 122 0.3 chemotherapy 611 0.3
5 全脑放疗 120 0.15 lung cancer 544 0.07
6 肺腺癌 84 0.06 cell lung cancer 538 0.19
7 放疗 83 0.12 non-cell lung cancer 538 0.11
8 靶向治疗 80 0.06 radiotherapy 447 0.2
9 疗效 75 0.08 stereotactic radiosurgery 424 0.33
10 化疗 54 0.22 open label 381 0.28
表6 WOS免疫治疗相关文献前10位关键词
序号 关键词 频次 中心性
1 brain metastases 143 0.07
2 open label 119 0.08
3 pembrolizumab 95 0.01
4 cell lung cancer 84 0.06
5 nivolumab 83 0.07
6 surival 82 0.06
7 chemotherapy 72 0.08
8 immunotherapy 71 0.16
9 docetaxel 63 0.05
10 stereotactic radiosurgery 62 0.03
1
Zhou Y, Guo T, Liang F, et al. Cumulative incidence and risk factors of brain metastases in metastatic non-small cell lung cancer without baseline brain metastasis: Pooled analysis of individualized patient data from IMpower130, IMpower131, and IMpower150[J]. Cancer, 2024, 130(15): 2601-2610.
2
Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024 [J]. CA Cancer J Clin, 2024, 74(1): 12-49.
3
中华医学会肿瘤学分会. 中华医学会肺癌临床诊疗指南(2024版) [J]. 中华医学杂志，2024, 104(34): 3175-3213.
4
Sereno M, Hernandez DE Córdoba I, et al. Brain metastases and lung cancer: molecular biology, natural history, prediction of response and efficacy of immunotherapy [J]. Front Immunol, 2023, 14: 1297988.
5
重庆肺癌精准治疗协作组，重庆市医药生物技术协会肿瘤罕见病疑难病专委会，重庆市医学会肿瘤学分会化疗学组. 非小细胞肺癌三代表皮生长因子受体酪氨酸激酶抑制剂耐药后诊疗策略专家共识(2025版)[J/OL]. 中华肺部疾病杂志(电子版), 2025, 18(6): 847-859.
6
Sperduto PW, Yang TJ, Beal K, et al. Estimating survival in patients with lung cancer and brain metastases: an update of the graded prognostic assessment for lung cancer using molecular markers (Lung-molGPA) [J]. JAMA Oncol, 2017, 3(6): 827-831.
7
Young LK, Halmos B. Immunotherapy for metastatic non-small cell lung cancer: Is it really a no-brainer? [J]. Cancer, 2024, 130(15): 2577-2581.
8
Getman V, Devyatko E, Dunkler D, et al. Prognosis of patients with non-small cell lung cancer with isolated brain metastases undergoing combined surgical treatment[J]. Eur J Cardiothorac Surg, 2004, 25(6): 1107-1113.
9
Wen P, Wang TF, Li M, et al. Meta-analysis of prophylactic cranial irradiation or not in treatment of extensive-stage small-cell lung cancer: The dilemma remains[J]. Cancer Radiother, 2020, 24(1): 44-52.
10
阙述浩，封巍，徐裕金. 免疫治疗联合化疗、放疗及靶向药物治疗小细胞肺癌脑转移的研究进展[J]. 肿瘤学杂志，2024, 30(3): 177-185.
11
段和新，田文韬，肖刚，等. 2021年恶性肿瘤脑转移研究现状和热点分析——基于CiteSpace可视化文献计量学研究 [J]. 国际神经病学神经外科学杂志，2022, 49(2): 38-47.
12
谭令，龙霖梓，邓秘，等. 抗血小板活化的文献计量学及可视化分析[J]. 世界科学技术-中医药现代化，2022, 24(1): 195-208.
13
Han B, Zheng R, Zeng H, et al. Cancer incidence and mortality in China, 2022[J]. J Natl Cancer Cent, 2024, 4(1): 47-53.
14
Mogenet A, Barlesi F, Besse B, et al. Molecular profiling of non-small-cell lung cancer patients with or without brain metastases included in the randomized SAFIR02-LUNG trial and association with intracranial outcome[J]. Lung Cancer, 2022, 169: 31-39.
15
魏明月，杨思怡，马瑜瑾，等. 基于CiteSpace的八角莲研究动态与发展趋势分析[J]. 世界科学技术-中医药现代化，2025, 27(2): 1-19.
16
Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer[J]. N Engl J Med, 2018, 378(2): 113-125.
17
Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC [J]. N Engl J Med, 2020, 382(1): 41-50.
18
Brown PD, Jaeckle K, Ballman KV, et al. Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: a randomized clinical trial[J]. JAMA, 2016, 316(4): 401-409.
19
Reungwetwattana t, Nakagawa k, Cho bc, et al. CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer[J]. J Clin Oncol, 2018: Jco2018783118.
20
Peters S, Camidge DR, Shaw AT, et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer[J]. N Engl J Med, 2017, 377(9): 829-838.
21
Goldberg SB, Gettinger SN, Mahajan A, et al. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial[J]. Lancet Oncol, 2016, 17(7): 976-983.
22
Goldberg SB, Schalper KA, Gettinger SN, et al. Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial[J]. Lancet Oncol, 2020, 21(5): 655-663.
23
凌金忠，李珊珊，朱国旗，等. 人参的文献计量学研究：热点与趋势分析[J]. 中草药，2024, 55(17): 5952-5963.
24
Yousefi M, Bahrami T, Salmaninejad A, et al. Lung cancer-associated brain metastasis: Molecular mechanisms and therapeutic options[J]. Cell Oncol (Dordr), 2017, 40(5): 419-441.
25
Besse B, Le Moulec S, Mazières J, et al. Bevacizumab in patients with nonsquamous non-small cell lung cancer and asymptomatic, untreated brain metastases (BRAIN): a nonrandomized, phase Ⅱ study[J]. Clin Cancer Res, 2015, 21(8): 1896-1903.
26
张语涵，李姗姗，刘浩. 非小细胞肺癌脑转移靶向治疗及免疫治疗进展[J]. 中国免疫学杂志，2022, 38(14): 1788-1794.
27
Mok TS, Wu YL, Ahn MJ, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer[J]. N Engl J Med, 2017, 376(7): 629-640.
28
Xing P, Wang S, Wang Q, et al. Efficacy of crizotinib for advanced ALK-rearranged non-small-cell lung cancer patients with brain metastasis: a multicenter, retrospective study in china[J]. Target Oncol, 2019, 14(3): 325-333.
29
Planchard D, Jänne PA, Cheng Y, et al. Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC[J]. N Engl J Med, 2023, 389(21): 1935-1948.
30
Masuda C, Sugimoto M, Wakita D, et al. Bevacizumab suppresses the growth of established non-small-cell lung cancer brain metastases in a hematogenous brain metastasis model[J]. Clin Exp Metastasis, 2020, 37(1): 199-207.
31
Mansfield AS, Herbst RS, De Castro G JR, et al. Outcomes with pembrolizumab monotherapy in patients with programmed death-ligand 1-positive NSCLC with brain metastases: pooled analysis of KEYNOTE-001, 010, 024, and 042 [J]. JTO Clin Res Rep, 2021, 2(8): 100205.
32
Mahajan A, Goldberg SL, Weiss SA, et al. Patterns of brain metastases response to immunotherapy with pembrolizumab [J]. J Neurooncol, 2024, 169(3): 555-561.
33
Passaro A, Wang J, Wang Y, et al. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase Ⅲ MARIPOSA-2 study [J]. Ann Oncol, 2024, 35(1): 77-90.
34
Yang Y, Deng L, Yang Y, et al. Efficacy and safety of combined brain radiotherapy and immunotherapy in non-small-cell lung cancer with brain metastases: a systematic review and meta-analysis[J]. Clin Lung Cancer, 2022, 23(2): 95-107.
35
Sheng J, Li H, Yu X, et al. Efficacy of PD-1/PD-L1 inhibitors in patients with non-small cell lung cancer and brain metastases: A real-world retrospective study in China [J]. Thorac Cancer, 2021, 12(22): 3019-3031.
36
Paz-Ares LG, Ramalingam SS, Ciuleanu TE, et al. First-line nivolumab plus ipilimumab in advanced NSCLC: 4-year outcomes from the randomized, open-label, phase 3 CheckMate 227 Part 1 Trial [J]. J Thorac Oncol, 2022, 17(2): 289-308.
37
刘靖，张文婷，苗传龙，等. 非小细胞肺癌患者脑转移风险预测模型的构建及验证[J]. 热带医学杂志，2023, 23(12): 1704-10，94.
38
朱池豪，王天伟，杨溪，等. 预测肺癌脑转移瘤预后的列线图研究[J]. 临床神经外科杂志，2023, 20(6): 658-663.
39
Akhoundova D, Hiltbrunner S, Mader C, et al. 18F-FET PET for diagnosis of pseudoprogression of brain metastases in patients with non-small cell lung cancer[J]. Clin Nucl Med, 2020, 45(2): 113-117.
40
Zuccato JA, Mamatjan Y, Nassiri F, et al. Prediction of brain metastasis development with DNA methylation signatures[J]. Nat Med, 2024, 31(1): 116-125.
41
Li BT, Smit EF, Goto Y, et al. Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer[J]. N Engl J Med, 2022, 386(3): 241-251.
[1] 刘彪, 杨成, 商中华. 嵌合抗原受体T细胞治疗胃肠道癌症的耐药机制与对策[J/OL]. 中华普通外科学文献(电子版), 2026, 20(05): 340-345.
[2] 李海波, 罗正宇, 武国. 转化治疗后手术切除联合术中消融治疗CNLC Ⅲa期肝细胞癌伴门静脉癌栓一例报告[J/OL]. 中华普外科手术学杂志(电子版), 2026, 20(05): 509-510.
[3] 潘溢恩, 黄吉炜. 上尿路尿路上皮癌保肾治疗进展[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2026, 20(05): 503-506.
[4] 王家瑞, 罗芮, 毕周奎, 廖晨, 徐智, 李亚斐, 白莉. 基于TCGA数据库慢性阻塞性肺疾病合并肺癌患者差异基因筛选及PI3K/AKT信号通路机制分析[J/OL]. 中华肺部疾病杂志(电子版), 2026, 19(05): 737-744.
[5] 龙铭, 贺斌峰, 李德峰, 高瞻, 秦蘅, 王关嵩. ADAM33基因多态性介导哮喘气道重塑及对免疫治疗效果影响的生物信息学研究[J/OL]. 中华肺部疾病杂志(电子版), 2026, 19(05): 786-796.
[6] 徐任莉, 谭明, 付敏, 李世强, 张杰, 朱高令, 陈亮. 液相芯片检测细胞因子表达与慢性阻塞性肺疾病合并肺癌关系分析[J/OL]. 中华肺部疾病杂志(电子版), 2026, 19(05): 820-825.
[7] 吴皎卿, 石进涛, 胡玉萍, 蒲嘉泽, 张长文, 李甜甜, 张莹, 卞春安, 陈豪, 杨玉春. 术前睡眠监测参数及血清NfL与慢性阻塞性肺疾病合并肺癌患者术后谵妄的相关性分析[J/OL]. 中华肺部疾病杂志(电子版), 2026, 19(04): 651-656.
[8] 乔山青, 张凤凯, 方剑, 张宏江, 薛瑞. 艾司氯胺酮联合胸腔镜引导胸椎旁阻滞对肺癌肺叶切除术后恢复与镇痛药物用量的影响[J/OL]. 中华肺部疾病杂志(电子版), 2026, 19(04): 663-669.
[9] 张静文, 马静, 杨轲, 贺晶, 王萍. 全程系统化肺康复管理在肺癌合并COPD患者单孔胸腔镜肺叶切除术中的应用研究[J/OL]. 中华肺部疾病杂志(电子版), 2026, 19(04): 680-683.
[10] 李秋韵, 王爽. 基于CT影像学评估非小细胞肺癌免疫治疗疗效的研究进展[J/OL]. 中华肺部疾病杂志(电子版), 2026, 19(04): 705-709.
[11] 陈典刚, 王欣欣, 黄露, 刘博. 基于单细胞RNA测序整合分析揭示肺腺癌肿瘤细胞恶性增殖的转录调控网络分析[J/OL]. 中华肺部疾病杂志(电子版), 2026, 19(04): 542-551.
[12] 刘慧, 赵燕霞, 汪海涛, 魏肖慧, 魏雪梅. CT肿瘤内部异质性对NSCLC患者免疫治疗反应性的预测价值[J/OL]. 中华肺部疾病杂志(电子版), 2026, 19(04): 560-565.
[13] 李可显, 钱浩, 邓侠兴. 胆囊癌规范化诊治及综合治疗进展[J/OL]. 中华肝脏外科手术学电子杂志, 2026, 15(05): 711-717.
[14] 罗希, 汤永生, 鲁旭, 李华. 免疫时代中晚期肝癌治疗新格局：联合策略、转化突破与精准预测[J/OL]. 中华肝脏外科手术学电子杂志, 2026, 15(04): 508-514.
[15] 林佳仪, 黄颖. Treg细胞在结直肠癌中的作用机制及靶向治疗研究进展[J/OL]. 中华结直肠疾病电子杂志, 2026, 15(04): 356-360.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号

AI
小
编
AI小编
你好！我是《中华医学电子期刊资源库》AI小编，有什么可以帮您的吗？